Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. develops small-molecule antibiotics for difficult-to-treat bacterial infections through a Gram-positive selective spectrum approach targeting DNA polymerase IIIC. Its pipeline includes ibezapolstat for Clostridioides difficile infection and additional DNA pol IIIC inhibitor candidates directed at Gram-positive pathogens such as MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis.
Recurring ACXP news covers antibiotic development updates, microbiome data, scientific conference presentations, intellectual property for DNA pol IIIC inhibitors, financial results, registered offerings, warrant activity and investor-presentation announcements.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported that following a July 13, 2026 FDA Type C Meeting, the Agency indicated it is open to considering a single Phase 3 trial (IBZ-ASPIRE) plus supportive data as the basis for an NDA for ibezapolstat in Clostridioides difficile infection (CDI), depending on the overall strength, consistency, and safety of the clinical results.
The FDA agreed that the planned ~550-patient, non-inferiority IBZ-ASPIRE trial, comparing ibezapolstat with vancomycin, could, if successful, support indications for both acute treatment and reduction of recurrence of CDI. FDA also stated that positive data from the open-label IBZ-PATHFINDER Phase 2 rCDI trial would support the NDA. If single-trial criteria are not met, FDA recommends a second Phase 3 study per the earlier EOP2 agreement. Acurx has initiated start-up for IBZ-PATHFINDER and is positioned to begin the international IBZ-ASPIRE trial, subject to funding, and continues to benefit from FDA QIDP and Fast-Track designations and EMA SME status.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported new microbiome and in vitro data on its antibiotic ibezapolstat in multiply‑recurrent Clostridioides difficile infection (rCDI), presented at the 18th Biennial Congress of the Anaerobe Society of the Americas.
According to Acurx and University of Houston researchers, beneficial gut bacteria involved in bile acid metabolism persist in patients with ≥2 CDI recurrences despite multiple prior vancomycin and/or fidaxomicin courses, and may regrow after ibezapolstat, which showed microbiome selectivity in earlier trials. Laboratory studies indicated ibezapolstat effectively killed C. difficile in planktonic and biofilm co‑culture with Enterococcus, outperforming fidaxomicin in biofilm killing and avoiding vancomycin‑associated VRE overgrowth. Acurx has initiated start‑up activities for a 20‑patient open‑label rCDI pilot trial and plans an active‑controlled Phase 3 rCDI registration trial, alongside an international Phase 3 program in acute CDI, supported by consistent FDA and EMA feedback and existing FDA QIDP/Fast Track and EMA SME designations.
Acurx Pharmaceuticals (NASDAQ: ACXP) will host a conference call on Friday, August 14, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and provide a business update.
The call will be led by President and CEO David P. Luci and CFO Robert G. Shawah.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported new structural biology results from its public‑private partnership with Leiden University Medical Center on DNA pol IIIC inhibitors, including lead candidate ibezapolstat.
High‑resolution cryo‑EM mapped ibezapolstat bound to Gram‑positive DNA pol IIIC at 3.2Å, supporting broad Gram‑positive targeting and informing Acurx’s preclinical pipeline for CDI, ABSSSI and inhalation anthrax.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported Q1 2026 results and business updates. Cash was $9.3M vs. $7.6M at year-end 2025, after raising about $3.1M via its equity line. Net loss narrowed to $1.7M ($0.62/share) from $2.1M.
The company advanced ibezapolstat for C. difficile, initiating a Phase 2 rCDI trial and preparing Phase 3 acute CDI studies, while expanding its global DNA pol IIIC patent estate with new U.S. and Korean grants.
Acurx (NASDAQ: ACXP) presented preclinical data at ESCMID Global 2026 showing that its DNA pol IIIC inhibitor candidates achieved systemic antibacterial activity against MRSA in neutropenic mice while preserving gut microbiome diversity compared with linezolid. The compounds reached potentially therapeutic plasma levels and maintained a Bacteroidota-dominant community, preventing Proteobacteria expansion.
Data suggest a class effect for microbiome-sparing Gram-positive antibiotics and note FDA QIDP and Fast-Track eligibility for Acurx preclinical candidates.
Acurx Pharmaceuticals (Nasdaq: ACXP) announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at the Alliance Global Partners Healthcare Company Showcase on Wednesday, May 24, 2025.
A replay will be available under the News / Events tab of the Acurx website at www.acurxpharma.com following the event.
Acurx Pharmaceuticals (NASDAQ: ACXP) will present at the Market Movers Investor Summit on Tuesday, May 5, 2026 at 5:20 PM ET at the historic Bank of New York, 48 Wall Street, New York.
David P. Luci, President and CEO, is scheduled to give the company presentation. Attendance requires an invitation via the summit website.
Acurx Pharmaceuticals (NASDAQ: ACXP) will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 a.m. ET before U.S. markets open. David P. Luci, president and CEO, and Robert G. Shawah, CFO, will host a conference call and provide a business update. Participant dial-in details and international toll-free numbers are available; U.S. access ID is 13760162.
Acurx Pharmaceuticals (NASDAQ: ACXP) closed a registered direct offering on April 16, 2026, selling 825,085 shares (or pre-funded warrants) at $3.03 per share for aggregate gross proceeds of approximately $2.5 million.
In a concurrent private placement the company issued immediately exercisable short-term warrants to purchase up to 1,650,170 shares at an exercise price of $2.78, exercisable for 24 months, which could raise an additional ~$4.6 million if fully exercised.